Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy

This study has been completed.
Napoli CTO Hospital
Information provided by:
Second University of Naples Identifier:
First received: December 3, 2009
Last updated: NA
Last verified: December 2009
History: No changes posted

The purpose of this study is to evaluate the role, the safety and the effectiveness of Intravitreal Bevacizumab injections as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy.

Condition Intervention Phase
Proliferative Diabetic Retinopathy
Drug: Bevacizumab
Other: sham
Phase 4

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy

Resource links provided by NLM:

Further study details as provided by Second University of Naples:

Arms Assigned Interventions
Active Comparator: 7 days Drug: Bevacizumab
Active Comparator: 20 days Drug: Bevacizumab
Sham Comparator: sham Other: sham


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • vitreous haemorrhage
  • tractional retinal detachment
  • active proliferative diabetic retinopathy.

Exclusion Criteria:

  • neovascular glaucoma
  • cataract
  • combined traction and rhegmatogenous RD
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided by Second University of Naples

Additional publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT01025934     History of Changes
Other Study ID Numbers: IVBDRNA
Study First Received: December 3, 2009
Last Updated: December 3, 2009
Health Authority: Italy: Ethics Committee

Additional relevant MeSH terms:
Retinal Diseases
Diabetic Retinopathy
Eye Diseases
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Growth Inhibitors
Antineoplastic Agents
Therapeutic Uses processed this record on October 19, 2014